Synageva Biopharma Corp (GEVA) 99.75 $GEVA
Synageva BioPharma Announces Presentations At 11th Annual World Symposium
PR Newswire - Wed Feb 11, 6:30AM CST
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today that data related to the company's programs will be the subject of three oral presentations and one poster presentation at the WORLDSymposium(TM) conference, February 9-13 in Orlando, Florida.
GEVA: 99.75 (-1.68)
An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You?
George Budwell, The Motley Fool - Motley Fool - Sun Feb 01, 12:02PM CST
The market activity of billionaire investors tends to attract a lot of attention because these billionaires are often perceived as having some kind of special insight into the direction of the broader market or individual stocks. In the world of...
ACAD: 34.21 (+0.37), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), GEVA: 99.75 (-1.68)
Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 5:25PM CST
Synageva BioPharma Corp. (GEVA) has commenced patient dosing in a phase I/II study on SBC-103 for mucopolysaccharidosis IIIB (also known as Sanfilippo B syndrome).
BMRN: 100.76 (+1.98), GEVA: 99.75 (-1.68), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted
PR Newswire - Mon Jan 26, 6:30AM CST
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today dosing with SBC-103 in patients with mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) has begun as part of a Phase 1/2 study. In addition, the U.S. Food and Drug Administration (FDA) recently granted SBC-103 Fast Track designation. Fast Track is a process designed to facilitate development and expedite review of drugs to treat serious and life-threatening conditions and fill an unmet medical need to get important new drugs to patients expeditiously.
GEVA: 99.75 (-1.68)
Why You Shouldn't Bet Against Synageva BioPharma (GEVA) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 7:58AM CST
Synageva BioPharma (GEVA) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
GEVA: 99.75 (-1.68)
3 Biotech Stocks Focused on Curing Ultra-Rare Diseases
Sean Williams, The Motley Fool - Motley Fool - Sun Jan 11, 1:41PM CST
Source: Food and Drug Administration. Biotech companies have a difficult battle they need to face on a daily basis. On one hand, they want to help as many people as possible and improve patients' quality of life around the globe with their...
GEVA: 99.75 (-1.68), BMRN: 100.76 (+1.98), ALXN: 182.29 (+6.02)
InsiderInsights.com Daily Round Up 1/9/15: OAS, OPK, RM, VVUS
InsiderInsights - at Seeking Alpha - Sun Jan 11, 12:09AM CST
PATK: 46.96 (+0.45), SVU: 10.21 (+0.04), VVUS: 2.68 (+0.13), BBY: 39.11 (-0.08), CRDS: 2.32 (+0.05), RM: 15.88 (+0.96), BRT: 6.98 (-0.02), WIW: 11.29 (unch), UNFI: 81.10 (+0.21), GEVA: 99.75 (-1.68), OPK: 13.80 (-0.28), CUDA: 35.68 (-1.14), NSAM: 22.02 (+0.27), WYY: 1.50 (+0.02), OAS: 16.84 (-0.03), RFP: 19.03 (+0.40), CRM: 62.85 (+1.59), NRF: 18.65 (+0.12)
Synageva BioPharma Announces Pricing of Public Offering of Common Stock
PR Newswire - Tue Jan 06, 6:07PM CST
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced the pricing of its previously announced underwritten public offering of common stock consisting of 3.0 million shares at $94.19 per share. In connection with this offering, Synageva granted to the underwriters a 30-day option to purchase 450,000 additional shares of common stock. If the underwriters exercise this option, Synageva will have offered 3.45 million shares of its common stock.
GEVA: 99.75 (-1.68)
Can The Uptrend Continue for Synageva Biopharma (GEVA)?
Synageva BioPharma Announces Presentations At 11th Annual World Symposium
PR Newswire - Wed Feb 11, 6:30AM CST
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today that data related to the company's programs will be the subject of three oral presentations and one poster presentation at the WORLDSymposium(TM) conference, February 9-13 in Orlando, Florida.
GEVA: 99.75 (-1.68)
An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You?
George Budwell, The Motley Fool - Motley Fool - Sun Feb 01, 12:02PM CST
The market activity of billionaire investors tends to attract a lot of attention because these billionaires are often perceived as having some kind of special insight into the direction of the broader market or individual stocks. In the world of...
ACAD: 34.21 (+0.37), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), GEVA: 99.75 (-1.68)
Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 5:25PM CST
Synageva BioPharma Corp. (GEVA) has commenced patient dosing in a phase I/II study on SBC-103 for mucopolysaccharidosis IIIB (also known as Sanfilippo B syndrome).
BMRN: 100.76 (+1.98), GEVA: 99.75 (-1.68), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted
PR Newswire - Mon Jan 26, 6:30AM CST
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today dosing with SBC-103 in patients with mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) has begun as part of a Phase 1/2 study. In addition, the U.S. Food and Drug Administration (FDA) recently granted SBC-103 Fast Track designation. Fast Track is a process designed to facilitate development and expedite review of drugs to treat serious and life-threatening conditions and fill an unmet medical need to get important new drugs to patients expeditiously.
GEVA: 99.75 (-1.68)
Why You Shouldn't Bet Against Synageva BioPharma (GEVA) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 7:58AM CST
Synageva BioPharma (GEVA) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
GEVA: 99.75 (-1.68)
3 Biotech Stocks Focused on Curing Ultra-Rare Diseases
Sean Williams, The Motley Fool - Motley Fool - Sun Jan 11, 1:41PM CST
Source: Food and Drug Administration. Biotech companies have a difficult battle they need to face on a daily basis. On one hand, they want to help as many people as possible and improve patients' quality of life around the globe with their...
GEVA: 99.75 (-1.68), BMRN: 100.76 (+1.98), ALXN: 182.29 (+6.02)
InsiderInsights.com Daily Round Up 1/9/15: OAS, OPK, RM, VVUS
InsiderInsights - at Seeking Alpha - Sun Jan 11, 12:09AM CST
PATK: 46.96 (+0.45), SVU: 10.21 (+0.04), VVUS: 2.68 (+0.13), BBY: 39.11 (-0.08), CRDS: 2.32 (+0.05), RM: 15.88 (+0.96), BRT: 6.98 (-0.02), WIW: 11.29 (unch), UNFI: 81.10 (+0.21), GEVA: 99.75 (-1.68), OPK: 13.80 (-0.28), CUDA: 35.68 (-1.14), NSAM: 22.02 (+0.27), WYY: 1.50 (+0.02), OAS: 16.84 (-0.03), RFP: 19.03 (+0.40), CRM: 62.85 (+1.59), NRF: 18.65 (+0.12)
Synageva BioPharma Announces Pricing of Public Offering of Common Stock
PR Newswire - Tue Jan 06, 6:07PM CST
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced the pricing of its previously announced underwritten public offering of common stock consisting of 3.0 million shares at $94.19 per share. In connection with this offering, Synageva granted to the underwriters a 30-day option to purchase 450,000 additional shares of common stock. If the underwriters exercise this option, Synageva will have offered 3.45 million shares of its common stock.
GEVA: 99.75 (-1.68)
Can The Uptrend Continue for Synageva Biopharma (GEVA)?
